VPS41-mediated neuroprotection in a Caenorhabditis elegans model of Parkinson’s disease

ISSN： 1479-6708

Source： Future Neurology, Vol.7, Iss.3, 2012-05, pp. : 255-258

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Neuroprotection of Pramipexole in UPS Impairment Induced Animal Model of Parkinson’s Disease

By Li Chao Guo Yuan Xie Wenjie Li Xingang Janokovic Joseph Le Weidong

Neurochemical Research, Vol. 35, Iss. 10, 2010-10 ,pp. : 1546-1556

Springer Publishing Company

Access to resources Recommend Favorite

Melatonin in Parkinson's disease

By Medeiros C.

Journal of Neurology, Vol. 255, Iss. 5, 2008-05 ,pp. : 759-759

Springer Publishing Company

Access to resources Recommend Favorite

A vaccine for Parkinson’s disease?

By Chesselet Marie-Francoise

Future Neurology, Vol. 1, Iss. 1, 2006-01 ,pp. : 21-23

Future Medicine

Access to resources Recommend Favorite

Pathophysiology of Parkinson’s disease

By Mandir Allen S. Vaughan Christina

International Review of Psychiatry, Vol. 12, Iss. 4, 2000-11 ,pp. : 270-280

Informa Healthcare

Access to resources Recommend Favorite

The Extent of Neurodegeneration and Neuroprotection in Two Chemical In Vitro Models Related to Parkinson's Disease is Critically Dependent on Cell Culture Conditions

By Jantas D.

Neurotoxicity Research, Vol. 24, Iss. 1, 2013-07 ,pp. : 41-54

Springer Publishing Company

Access to resources Recommend Favorite